AbbVie Inc. (ABBV)
Pre-market:
| Previous close | 157.06 |
| Open | 156.35 |
| Bid | 153.63 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 153.95 - 156.35 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,642,011 |
| Market cap | 274.31B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 46.79 |
| EPS (TTM) | 3.32 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 6.20 (3.95%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 183.11 |
PR NewswireAbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024). AbbVie's ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein), which are over-expressed across various tumor types. By utilizing these biomarkers as targets, ADCs are
- PR Newswire
AbbVie Completes Acquisition of Landos Biopharma
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. (NASDAQ: LABP). With the completion of the acquisition, Landos is now part of AbbVie.
ZacksWhy AbbVie (ABBV) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
